Title:Novel Therapeutic Targets for Management of Type-2 Diabetes Mellitus
Volume: 16
Issue: 1
Author(s): Anishkumar Chaurasia, Rashmi Mallya and Tabassum Khan
Affiliation:
Keywords:
11-Hydroxysteroid dehydrogenase type 1 inhibitors, glucagon receptor antagonist, glucokinase
activators, incretin mimetics, liver x receptors, type-2 Diabetes Mellitus.
Abstract: A number of conventional therapeutic targets are available for
treatment of Type 2 diabetes mellitus (T2DM) but due to development of
resistance by using conventional drug as monotherapy, there is a need to identify
novel therapeutic targets and/or use combination of conventional and
novel drugs for diabetes therapy. In this review we have highlighted some of
the novel approaches like inhibitors of (11- Hydroxysteroid dehydrogenase type-1, Sodium-glucose linked
cotransporter-2, Acyl-CoA Diacylglycerol Acyl Transferase-1, Glycogen phosphorylase-A, Pyruvate Dehydrogenase
Kinase, Protein tyrosine phosphate 1B, Kappa kinase-B, Stearoyl-coA desaturase-1), antagonists of
(Fatty acid binding proteins, Fibroblast growth factors-21 receptor, Glucagon receptor, Glucocorticoid receptors),
Glucokinase and Sirtuin activators, Cannabinoid receptor blockers, Incretin-mimetics, agonists of
(Adenosine monophosphate activated protein kinase, Augmenting GLP-1 secretion GPR40, GPR120, GPR
146 and TGR 5, GPCR 119, liver x receptors, Serotonin 2c receptor) and Rexinoids x receptor modulators
developed for the treatment of diabetes.